Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies
| Autor: | Juan Chipollini, Walter Henriques da Costa, Isabela Werneck da Cunha, Felipe de Almeida e Paula, Paulo Guilherme O. Salles, Mounsif Azizi, Philippe E. Spiess, Diego Abreu, Stênio de Cássio Zequi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Urology, Vol 11 (2019) |
| Druh dokumentu: | article |
| ISSN: | 1756-2880 17562872 |
| DOI: | 10.1177/1756287219882600 |
| Popis: | Background: We aimed to evaluate the prognostic role of programmed-death receptor ligand (PD-L1) in a multinational cohort of patients with localized renal cell carcinoma (RCC). Methods: Formalin-fixed paraffin-embedded blocks of 1017 patients from the Latin American Renal Cancer Group were analyzed. Tissue microarrays were immunostained for PD-L1 using a commercially available monoclonal antibody. Expression of PD-L1 in ⩾5% tumor cells was considered positive. PD-1 expression in immune cells was also assessed. All cases were reviewed twice based on antibody expression and compared with a positive control. Cox proportional hazard regression models were used to identify predictors of recurrence-free survival (RFS) and overall survival (OS). Results: A total of 738 cases with complete follow up met criteria. Median age was 57 [interquartile range (IQR): 49–64] years, and median follow up was 34 (IQR: 15–62.9) months. Median tumor size was 5 cm (IQR: 3.0–7.5 cm). Approximately 8.2% and 7.6% of tumors were PD-L1 and programmed cell-death 1 (PD-1) positive, respectively. PD-L1 and PD-1 positivity were significantly associated with higher tumor stage (both p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|